文献速递皮肤肿瘤

原位黑色素瘤幸存者第二原发癌的风险

Risk of Second Primary Cancer in Survivors of In Situ Melanoma.
PubMed 文献 · J Invest Dermatol · 2018-11-10

研究评估澳大利亚昆士兰1982年至2012年诊断的39,872例首发原位黑色素瘤幸存者,共4,823例(12%)发生第二原发癌。与一般人群相比总体风险小幅增加6%,50岁以下者所有癌症合并风险增加14%。原位黑色素瘤幸存者唇、甲状腺、胰腺和脑癌风险显著升高,头颈癌和肺癌风险降低。

要点

  • 39,872例原位黑色素瘤幸存者中4,823例(12%)发生第二原发癌,总体风险较一般人群增加6%。
  • 50岁以下幸存者所有癌症合并风险增加14%。
  • 唇、甲状腺、胰腺、脑癌风险显著升高,头颈癌和肺癌风险降低。

核心结论

  • 原位黑色素瘤可能预测某些第二原发癌的诊断,这种风险改变可能源于生物学、行为或遗传因素或医疗监测增加,需进一步研究,尤其是50岁以下人群。

研究设计与样本

  • 基于澳大利亚昆士兰1982年至2012年诊断的39,872例首发原位黑色素瘤幸存者的研究,采用标准化发病比及95%置信区间估计第二非黑色素瘤原发癌的相对风险。

主要发现

  • 共4,823例(12%)原位黑色素瘤幸存者发生第二原发癌,与一般人群相比风险小幅增加6%。
  • 50岁以下者所有癌症合并风险增加14%。
  • 原位黑色素瘤幸存者唇癌、甲状腺癌、胰腺癌和脑癌风险显著升高,头颈癌和肺癌风险降低。
  • 男性幸存者前列腺癌风险显著升高,女性幸存者甲状腺癌和淋巴细胞白血病风险升高。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文指出这种风险改变可能源于生物学、行为或遗传因素或医疗监测增加,需进一步研究,尤其是50岁以下人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Survivors of invasive melanoma have an increased risk of developing second primary cancers; however, similar risks associated with in situ melanoma have not been established. We evaluated 39,872 survivors of first primary in situ melanoma diagnosed from 1982 through 2012 in Queensland, Australia. Relative risk of second nonmelanoma primary cancers was estimated from standardized incidence ratios with 95% confidence intervals. A total of 4,823 (12%) in situ melanoma survivors developed a second primary cancer. A small increased risk (6%) compared with the general population was found. In those younger than 50 years, risk was increased by 14% for all cancers combined. In situ melanoma survivors had significantly increased risks of developing lip, thyroid, pancreatic, and brain cancers and decreased risks of head and neck, and lung cancers. Male in situ melanoma survivors had a significantly increased risk of prostate cancer; female survivors had an increased risk of thyroid cancer and lymphoid leukemia. Findings indicate that in situ melanoma may predict the diagnosis of certain second primary cancers. This altered risk may be due to biological, behavioral, or genetic factors or increased medical surveillance, and it requires further investigation, particularly among people younger than 50 years.

来源:J Invest Dermatol,查看原文。版权归原作者所有。

引用

  1. Kimlin MG, Youlden DR, Brodie AM, et al. Risk of Second Primary Cancer in Survivors of In Situ Melanoma. J Invest Dermatol. 2018. PMID: 30423330. doi:10.1016/j.jid.2018.11.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。